Published on
Apr 16, 2025
Molecular Profiling, Endocrine Sensitivity Are Key to Managing Later-Line HR+/HER2-Negative Breast Cancer
Although the combination of an aromatase inhibitor (AI) and a CDK4/6 inhibitor remains the standard of care for frontline management of advanced hormone receptor (HR)–positive, HER2-negative breast cancer, an increasing reliance on molecular profiling …
Source:
OncLive
-
Pending
